Rep. Josh Gottheimer Sells Genmab A/S (NASDAQ:GMAB) Shares

Representative Josh Gottheimer (D-New Jersey) recently sold shares of Genmab A/S (NASDAQ:GMAB). In a filing disclosed on January 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Genmab A/S stock on December 16th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Block (NYSE:SQ) on 12/30/2024.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/30/2024.
• Sold $1,001 – $15,000 in shares of Ambev (NYSE:ABEV) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Grupo Financiero Banorte (OTCMKTS:GBOOY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Cadre (NYSE:CDRE) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Coloplast A/S (OTCMKTS:CLPBY) on 12/27/2024.
• Sold $1,001 – $15,000 in shares of Intuitive Surgical (NASDAQ:ISRG) on 12/23/2024.
• Sold $1,001 – $15,000 in shares of Trane Technologies (NYSE:TT) on 12/23/2024.
• Purchased $1,001 – $15,000 in shares of Walmart (NYSE:WMT) on 12/20/2024.
• Sold $1,001 – $15,000 in shares of NVIDIA (NASDAQ:NVDA) on 12/19/2024.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $20.23 on Thursday. Genmab A/S has a one year low of $19.85 and a one year high of $31.88. The company has a market capitalization of $13.39 billion, a price-to-earnings ratio of 19.64, a price-to-earnings-growth ratio of 0.63 and a beta of 0.97. The company’s 50-day simple moving average is $21.27 and its two-hundred day simple moving average is $24.15.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the previous year, the business earned $0.47 earnings per share. Equities analysts expect that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after acquiring an additional 1,051 shares during the period. Blue Trust Inc. increased its holdings in shares of Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after purchasing an additional 1,413 shares during the last quarter. Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Genmab A/S by 7.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the period. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, January 8th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, Redburn Atlantic initiated coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Genmab A/S presently has an average rating of “Moderate Buy” and an average target price of $45.20.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer’s career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer’s committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.